Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000

Part (ii) All adults (aged 15–64)

Country

Geographical area

Year

Reference

Age range all adults

Sample size all adults

Cannabis (%)

Cocaine (%) (1)

Amphetamines (%) (2)

Ecstasy (%) (3)

LSD (%)

Belgium

National

2008

(7)

15–64

6792

14.3

:

:

:

:

Bulgaria

National

2008

(3)

15–64

5139

7.3

1.7

2.1

1.7

0.2

Czech Republic

National

2011

(8)

15–64

901

24.9

1.4

2.1

5.8

2.1

Denmark

National

2010

(6)

16–64

11611

32.5

4.4

6.2

2.1

1.3

Germany

National

2009

(8)

18–64

8030

25.6

3.3

3.7

2.4

2.4

Estonia

National

2008

(3)

15–64

1401

:

:

:

:

:

Ireland

National

2010–11

(6)

15–64

5128

25.3

6.8

4.5

6.9

4.4

Greece

National (except Aegean and Ionian Islands)

2004

(3)

15–64

4351

8.9

0.7

0.1

0.4

0.3

Spain

National

2011

(9)

15–64

22128

27.4

8.8

3.3

3.6

:

France

National

2010

(7)

15–64

22774

32.1

3.7

1.7

2.4

1.7

Italy

(4)

National

2012

(5)

18–64

18898

21.7

4.2

1.8

1.8

0.7

Cyprus

National

2009

(2)

15–64

3385

11.6

3.0

0.7

2.0

1.3

Latvia

National

2011

(3)

15–64

4491

12.5

1.5

2.2

2.7

0.7

Lithuania

National

2008

(2)

15–64

4777

11.9

0.5

1.6

2.1

0.4

Luxembourg

:

:

:

:

:

:

:

:

:

:

Hungary

National

2007

(3)

18–64

2710

8.5

0.9

1.8

2.4

1.1

Malta

National

2001

(1)

18–64

1755

3.5

0.4

0.4

0.7

0.5

Netherlands

(5)

National

2009

(4)

15–64

5769

25.7

5.2

3.1

6.2

1.5

Austria

National

2008

(2)

15–64

3761

14.2

2.2

2.5

2.3

1.9

Poland

National

2010

(3)

15–64

5782

17.5

1.3

4.2

3.4

2.0

Portugal

National

2007

(2)

15–64

12202

11.7

1.9

0.9

1.3

0.6

Romania

National

2010

(3)

15–64

5100

1.6

0.3

0.1

0.7

0.1

Slovenia

National

2007

(1)

15–64

1724

:

:

:

:

:

Slovakia

National

2010

(7)

15–64

4055

10.5

0.6

0.5

1.9

0.4

Finland

National

2010

(8)

15–64

1873

18.3

1.7

2.3

1.8

1.0

Sweden

National

2008

(5)

15–64

22095

21.4

3.3

5.0

2.1

:

Sweden

National

2011

(13)

16-64

6964

14.2

:

:

:

:

United Kingdom

England and Wales

2011-12

(15)

16-59

26663

31.0

9.6

11.5

8.6

5.3

United Kingdom

Northern Ireland

2010-11

(21)

15–64

2533

24.0

6.7

6.3

8.8

5.1

United Kingdom

Scotland

2010-11

(27)

16–64

8232

26.7

8.9

9.8

9.0

6.2

United Kingdom

United Kingdom

2006

(29)

16–59

:

30.2

7.7

11.9

7.5

5.6

Croatia

National

2012

(1)

15–64

4756

15.6

2.3

2.6

2.5

1.4

Turkey

National

2011

(1)

15–64

8045

0.7

:

0.3

0.1

:

Norway

National

2009

(3)

15–64

1624

14.6

2.5

3.8

1.0

0.9

Notes:

This table presents the methods and results for the last surveys available in each country. The number indicated in the ‘Ref.’ column is the reference to the corresponding survey in the table presenting all surveys available for each country in Table GPS-7. For sources of each survey see Table GPS-0.

(1) Cocaine, any form.

(2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy.

(3) For Spain: ecstasy and other designer drugs.

(4) The most recent general population survey reported by Italy display a wide variation in results compared with the previous surveys which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

(5) The most recent general population survey reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as reference point for the 1993 survey.

In surveys with small sample sizes results should be interpreted with caution.

Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.

For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions.